Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This ...

With a market cap of $18.4 billion, Insulet Corporation (PODD) is a leading developer of innovative insulin delivery systems ...

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient ...

Just shy of two years after a C-suite reorganization at Insulet, Mark Field has left his position as the inaugural chief ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...

Corporation shared new Omnipod 5 clinical data from its RADIANT study. Results from this multinational randomized controlled ...

Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...

Insulet Corporation PODD has witnessed strong momentum in the past year. Shares of the company have risen 62.9% compared with 9.9% growth of the industry during the same time frame. The S&P 500 ...

Shares of Insulet Corp. PODD slipped 1.74% to $260.27 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.33% to 5,693.31 and ...